Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease: A case report

Hideyuki Niwa; Sakiko Otani; Norihiro Nakada; Jiichiro Sasaki; Hideo Saka; Noriyuki Masuda

Respiratory Medicine Case Reports (Jan 2018)

Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease: A case report

Hideyuki Niwa,
Sakiko Otani,
Norihiro Nakada,
Jiichiro Sasaki,
Hideo Saka,
Noriyuki Masuda

Affiliations

Hideyuki Niwa: Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan; Department of Respiratory Medicine, Nagoya Medical Center, Nagoya, Aichi, Japan; Corresponding author. Department of Respiratory Medicine, Nagoya Medical Center, 4-1-1 Sannomaru Naka-ku, Nagoya, Aichi, 460-0001, Japan.
Sakiko Otani: Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan
Norihiro Nakada: Department of Pathology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan
Jiichiro Sasaki: Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Kanagawa, Japan
Hideo Saka: Department of Respiratory Medicine, Nagoya Medical Center, Nagoya, Aichi, Japan
Noriyuki Masuda: Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan

Journal volume & issue: Vol. 23
pp. 131 – 135

Abstract

Read online

Carcinosarcoma is a rare histological type of non-small cell carcinoma (NSCLC), and its prognosis has been reported to be worse compared with other NSCLCs. Nanoparticle albumin-bound paclitaxel (nab-PTX) + carboplatin (CBDCA) achieves a favorable response rate in patients with non-small cell lung cancer (NSCLC). We administered nab-PTX + CBDCA to a 68-year-old man with postoperative recurrent carcinosarcoma with interstitial lung disease (ILD). A partial response was evident after four cycles of chemotherapy. To the best of our knowledge, the present study is the first to report the safety and efficacy of nab-PTX + CBDCA for treating carcinosarcoma with ILD. Keywords: Carcinosarcoma, Chemotherapy, Nab-paclitaxel, Carboplatin, Interstitial lung disease

Published in Respiratory Medicine Case Reports

ISSN: 2213-0071 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the respiratory system
Website: http://www.journals.elsevier.com/respiratory-medicine-case-reports/

About the journal